Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
603590 Beijing Konruns Pharmaceutical
- 25.39
- -0.09-0.35%
Market Closed Dec 20 15:00 CST
4.06BMarket Cap35.41P/E (TTM)
25.60High25.28Low8.88KlotVolume25.40Open25.48Pre Close22.58MTurnover0.56%Turnover Ratio27.01P/E (Static)160.00MShares38.0652wk High1.27P/B4.00BFloat Cap20.0752wk Low28.03Limit Up157.73MShs Float55.83Historical High22.93Limit Down1.26%Amplitude20.07Historical Low0.30Dividend TTM25.43Avg Price4.68KlotAsk1.18%Div YieldTTM100Lot Size4.00KlotBid
Beijing Konruns Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -10.24%646.31M | -10.16%405.02M | 20.67%199.24M | 6.15%920.01M | 22.46%720.04M | 21.33%450.84M | 5.71%165.11M | 7.03%866.73M | -1.44%587.99M | -18.43%371.59M |
| Operating revenue | -10.24%646.31M | -10.16%405.02M | 20.67%199.24M | 6.15%920.01M | 22.46%720.04M | 21.33%450.84M | 5.71%165.11M | 7.03%866.73M | -1.44%587.99M | -18.43%371.59M |
| Other operating revenue | ---- | -73.94%491.76K | ---- | -85.60%2.26M | ---- | -88.02%1.89M | ---- | -86.57%15.68M | ---- | -81.65%15.76M |
| Total operating cost | -5.54%518.43M | -8.70%317.15M | 11.98%150.67M | 6.36%773.68M | 8.37%548.85M | 9.21%347.35M | 5.51%134.55M | 8.14%727.45M | 9.78%506.47M | -11.94%318.06M |
| Operating cost | -6.17%68.71M | -10.74%42.39M | 27.67%22.46M | -19.90%101.05M | -14.33%73.22M | -12.44%47.49M | -17.26%17.59M | 19.29%126.16M | 9.24%85.48M | -1.26%54.23M |
| Operating tax surcharges | 11.97%5.19M | 14.00%3.46M | -4.88%1.33M | -9.19%5.9M | -7.54%4.64M | -15.34%3.03M | -12.96%1.4M | -25.24%6.5M | -26.06%5.01M | -31.37%3.58M |
| Operating expense | -6.43%322.35M | -11.75%193.75M | 19.72%90.45M | 11.68%472.59M | 13.51%344.49M | 17.42%219.53M | 5.61%75.55M | 8.14%423.15M | 14.95%303.49M | -13.59%186.97M |
| Administration expense | 26.96%89.28M | 22.07%56.52M | 26.78%26.16M | 7.76%110.7M | -4.86%70.32M | -3.12%46.3M | -0.16%20.64M | 16.66%102.72M | 15.93%73.91M | 11.83%47.79M |
| Financial expense | 80.69%-2.13M | 75.66%-2.26M | 43.70%-1.05M | 35.84%-11.46M | 31.54%-11.03M | 8.53%-9.29M | 56.33%-1.87M | 23.65%-17.86M | 10.01%-16.12M | 16.55%-10.15M |
| -Interest expense (Financial expense) | 255.98%4.38M | 328.56%2.64M | 314.84%1.23M | 221.89%2.78M | 117.45%1.23M | 55.42%615.48K | 42.45%297.32K | -38.66%864.06K | -46.15%565.22K | -50.95%396.02K |
| -Interest Income (Financial expense) | 4.55%-9.56M | 7.47%-6.36M | 9.92%-2.92M | 25.63%-13.77M | 31.38%-10.02M | 29.82%-6.87M | 28.90%-3.24M | 24.65%-18.52M | 22.75%-14.59M | 22.72%-9.79M |
| Research and development | -47.87%35.04M | -42.18%23.29M | -46.72%11.32M | 9.38%94.91M | 22.87%67.22M | 13.01%40.29M | 26.98%21.24M | -15.15%86.78M | -17.66%54.71M | -34.08%35.65M |
| Credit Impairment Loss | 71.98%-585.17K | -124.61%-180.06K | -100.30%-4.22K | -232.40%-7.25M | -317.39%-2.09M | -117.11%-80.17K | -31.28%1.39M | -578.90%-2.18M | 161.26%960.72K | 127.83%468.43K |
| Asset Impairment Loss | ---- | ---- | ---- | -161.49%-11.91M | ---- | ---- | ---- | ---4.56M | ---- | ---- |
| Other net revenue | -4.70%16.52M | -23.90%13.05M | -67.86%1.7M | -313.40%-3.04M | -59.93%17.34M | -60.60%17.15M | -79.49%5.28M | -97.41%1.43M | 87.07%43.26M | 141.92%43.54M |
| Fair value change income | 197.48%1.6M | 153.15%923.48K | 100.59%1.05M | 86.81%-866.8K | -1,337.16%-1.64M | ---1.74M | -20.09%522.45K | -115.76%-6.57M | --132.62K | ---- |
| Invest income | 13.15%12.2M | -0.53%10.11M | -138.89%-536.93K | 616.30%5.56M | -61.86%10.78M | -65.16%10.16M | -93.57%1.38M | 82.17%-1.08M | 326.71%28.27M | 315.12%29.18M |
| -Including: Investment income associates | 78.42%-409.16K | -20.72%-1.22M | -91.44%-657.01K | 7.20%-8.79M | -109.38%-1.9M | -104.77%-1.01M | -101.60%-343.2K | -225.96%-9.47M | 1,502.43%20.22M | 2,132.89%21.12M |
| Asset deal income | ---7.33K | ---- | ---- | ---8.23K | ---- | ---- | ---- | ---- | ---- | ---- |
| Other revenue | -67.78%3.31M | -75.01%2.2M | -40.15%1.19M | -27.69%11.43M | -26.02%10.28M | -36.61%8.81M | 25.91%1.99M | -17.07%15.81M | -23.09%13.9M | 9.82%13.9M |
| Operating profit | -23.40%144.4M | -16.33%100.93M | 40.27%50.26M | 1.83%143.28M | 51.09%188.53M | 24.28%120.64M | -34.14%35.83M | -26.83%140.7M | -21.22%124.78M | -13.63%97.07M |
| Add:Non operating Income | -99.48%1.34K | -98.29%978.72 | -99.11%444.93 | -48.38%261.5K | -49.07%257.56K | 1,201.68%57.38K | 2,292.92%50.19K | -87.64%506.62K | 9,282.50%505.72K | 203.60%4.41K |
| Less:Non operating expense | -81.11%190.5K | -83.91%129.65K | -100.00%26.66 | 2,229.06%20.81M | 58.03%1.01M | 238.14%805.78K | 1,194.09%802.24K | -88.14%893.56K | 19.52%638.3K | 1,705.46%238.3K |
| Total profit | -23.20%144.21M | -15.92%100.8M | 43.28%50.26M | -12.53%122.73M | 50.64%187.77M | 23.81%119.89M | -35.45%35.08M | -25.70%140.32M | -21.04%124.65M | -13.82%96.83M |
| Less:Income tax cost | -17.03%20.69M | -18.12%13.52M | -34.48%3.42M | -494.83%-64.84M | 146.32%24.94M | 135.22%16.52M | 33.49%5.22M | -23.32%16.42M | -35.07%10.12M | -43.12%7.02M |
| Net profit | -24.14%123.52M | -15.57%87.28M | 56.86%46.85M | 51.40%187.57M | 42.19%162.84M | 15.10%103.37M | -40.79%29.86M | -26.01%123.89M | -19.50%114.52M | -10.21%89.81M |
| Net profit from continuing operation | -24.14%123.52M | -15.57%87.28M | 56.86%46.85M | 51.40%187.57M | 42.19%162.84M | 15.10%103.37M | -40.79%29.86M | -26.01%123.89M | -19.50%114.52M | -10.21%89.81M |
| Less:Minority Profit | -25.75%10.55M | -22.95%8.08M | 23.72%5.19M | 65.68%37.12M | 30.87%14.21M | 34.88%10.48M | 4.80%4.2M | 15.16%22.4M | 114.69%10.85M | 2,606,814.58%7.77M |
| Net profit of parent company owners | -23.99%112.98M | -14.73%79.2M | 62.28%41.65M | 48.24%150.45M | 43.37%148.63M | 13.23%92.89M | -44.72%25.67M | -31.42%101.49M | -24.45%103.67M | -17.98%82.04M |
| Earning per share | ||||||||||
| Basic earning per share | -24.31%0.7189 | -15.25%0.5 | 68.75%0.27 | 47.69%0.96 | 43.37%0.9498 | 13.46%0.59 | -46.67%0.16 | -30.85%0.65 | -23.88%0.6625 | -17.46%0.52 |
| Diluted earning per share | -24.31%0.7189 | -15.25%0.5 | 68.75%0.27 | 47.69%0.96 | 43.37%0.9498 | 13.46%0.59 | -46.67%0.16 | -30.85%0.65 | -23.88%0.6625 | -17.46%0.52 |
| Other composite income | 12.83%51.6M | -80.19%18.88M | -53.15%38.11M | 125.51%6.3M | 179.41%45.73M | 330.76%95.33M | 524.86%81.34M | 85.60%-24.69M | 68.78%-57.58M | 72.80%-41.31M |
| Other composite income of parent company owners | 12.83%51.6M | -80.19%18.88M | -53.15%38.11M | 125.51%6.3M | 179.41%45.73M | 330.76%95.33M | 524.86%81.34M | 85.60%-24.69M | 68.16%-57.58M | 72.80%-41.31M |
| Total composite income | -16.04%175.12M | -46.57%106.16M | -23.60%84.95M | 95.43%193.87M | 266.26%208.57M | 309.68%198.7M | 255.34%111.2M | 2,567.29%99.2M | 235.09%56.94M | 193.52%48.5M |
| Total composite income of parent company owners | -15.33%164.57M | -47.89%98.08M | -25.46%79.76M | 104.11%156.75M | 321.70%194.36M | 362.13%188.22M | 292.09%107.01M | 427.13%76.8M | 205.58%46.09M | 178.53%40.73M |
| Total composite income of minority owners | -25.75%10.55M | -22.95%8.08M | 23.72%5.19M | 65.68%37.12M | 30.87%14.21M | 34.88%10.48M | 4.80%4.2M | 15.16%22.4M | 623.40%10.85M | 2,606,814.58%7.77M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Huaxing Certified Public Accountants Firm (Special General Partnership) | -- | -- | -- | Huaxing Certified Public Accountants Firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
